Trial Profile
An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2020
Price :
$35
*
At a glance
- Drugs Human skin replacement (Primary)
- Indications Burns; Skin disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Stratatech
- 06 Apr 2020 According to an Mallinckrodt plc media release, data from this study is accepted for presentation at the American Burn Association 52nd Annual Meeting.
- 13 Aug 2019 Results presented in a Mallinckrodt plc media release.
- 19 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.